Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/113446
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aerts, Céline | - |
dc.contributor.author | Sunyoto, Temmy | - |
dc.contributor.author | Tediosi, Fabrizio | - |
dc.contributor.author | Sicuri, Elisa | - |
dc.date.accessioned | 2017-07-06T12:32:09Z | - |
dc.date.available | 2018-05-19T22:01:41Z | - |
dc.date.issued | 2017-05-19 | - |
dc.identifier.issn | 0168-8510 | - |
dc.identifier.uri | http://hdl.handle.net/2445/113446 | - |
dc.description.abstract | Pharmaceutical companies are reluctant to invest in research and development (R&D) of products for neglected tropical diseases (NTDs) mainly due to the low ability-to-pay of health insurance systems and of potential consumers. The available preventive and curative interventions for NTDs mostly rely on old technologies and products that are often not adequate. Moreover, NTDs mostly affect populations living in remote rural areas and conflict zones, thereby hampering access to healthcare. The challenges posed by NTDs have led to the proliferation of a variety of public-private partnerships (PPPs) in the last decades. We conducted a systematic review to assess the functioning and impact of these partnerships on the development of and access to better technologies for NTDs. Our systematic review revealed a clear lack of empirical assessment of PPPs: we could not find any impact evaluation analyses, while these are crucial to realize the full potential of PPPs and to progress further towards NTDs elimination. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B. V. | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1016/j.healthpol.2017.05.005 | - |
dc.relation.ispartof | Health Policy, 2017, vol. 121, num. 7, p. 745-754 | - |
dc.relation.uri | http://dx.doi.org/10.1016/j.healthpol.2017.05.005 | - |
dc.rights | cc by-nc-nd (c) Elsevier B. V., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Medicina tropical | - |
dc.subject.classification | Indústria farmacèutica | - |
dc.subject.classification | Salut pública | - |
dc.subject.classification | Avaluació del risc per la salut | - |
dc.subject.other | Tropical medicine | - |
dc.subject.other | Pharmaceutical industry | - |
dc.subject.other | Public health | - |
dc.subject.other | Health risk assessment | - |
dc.title | Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2017-06-21T18:00:42Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/642609/EU//EUROLEISH-NET | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28579276 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
aerts20172568.pdf | 543.93 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License